Alison Le Poidevin

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Sarah F. Griffee, Susan M. Kilroy, Philip Smith, 2022, The Lancet Gastroenterology & Hepatology.

Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial.

Mohammed Salah Ibrahim, M. Antonelli, G. Grasselli, 2021, The Lancet. Respiratory medicine.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Susan M. Kilroy, C. Lees, T. Ahmad, 2022, Nature Communications.